778 related articles for article (PubMed ID: 26907204)
1. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Liu R; Wang J; Tang W; Fang H
Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
3. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
4. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
[TBL] [Abstract][Full Text] [Related]
6. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
[TBL] [Abstract][Full Text] [Related]
9. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities.
Yang F; Peng S; Li Y; Su L; Peng Y; Wu J; Chen H; Liu M; Yi Z; Chen Y
Org Biomol Chem; 2016 Feb; 14(5):1727-35. PubMed ID: 26732459
[TBL] [Abstract][Full Text] [Related]
10. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
11. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
[TBL] [Abstract][Full Text] [Related]
12. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
13. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
16. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
[TBL] [Abstract][Full Text] [Related]
17. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.
Zhou Y; Dun Y; Fu H; Wang L; Pan X; Yang X; Fang H
Chem Biol Drug Des; 2017 Nov; 90(5):936-942. PubMed ID: 28489276
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
20. Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
Ling Y; Guo J; Yang Q; Zhu P; Miao J; Gao W; Peng Y; Yang J; Xu K; Xiong B; Liu G; Tao J; Luo L; Zhu Q; Zhang Y
Eur J Med Chem; 2018 Jan; 144():398-409. PubMed ID: 29288941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]